Skip to main content

Advertisement

Log in

Intraspinal baclofen in the treatment of severe spasticity and spasms

  • Clinical Articles
  • Published:
Acta Neurochirurgica Aims and scope Submit manuscript

Summary

Ten patients with severe spasticity were evaluated according to a standardized protocol in order to be treated by intraspinal baclofen. Entry criteria in the protocol were the following: 1) Stable central nervous system lesion, 2) Severe spasticity and/or flexo-extensor spasms not controllable by oral treatment, 3) Normal CSF circulation and 4) Informed consent. All patients received a test dose of twenty-five micrograms of baclofen injected intrathecally. At intervals of at least one day, doses were increased in 10–25 microgram steps until total abolition of spontaneous spasms was achieved in complete spinal cord lesions. In patients with residual motor function, doses were titrated until the optimal dose was found that reduced spasms and enabled performance of maximum daily life activities according to the patient's neurological level.

In nine patients a multidose reservoir was implanted to deliver intrathecal baclofen. Effective dosage was 60±31 micrograms in the entire group. Ashworth score was reduced from 4.6±0.7 to 1.2±0.4 (mean±SD) (p<0.0001) and spasms from 3.2±0.8 to 0.2±0.4 (p<0.0001).

Follow-up of the nine patients in whom a reservoir was implanted has been 18±9 months. Initial dosage requirements and tolerance were significantly different in complete (Frankel's A grade) or incomplete lesions (Frankel's B, C and D grades). Complete spinal cord lesions required a greater initial dose (156±43) than incomplete lesions (44±24), these differences being statistically significant (Student's t-test, p<0.05). Tolerance was observed only in patients with complete motor and complete sensory lesions. In incomplete lesions, dose increase was insignificant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Davidoff RA (1985) Antispasticity drugs: mechanisms of action. Ann Neurol 17: 107–116

    PubMed  Google Scholar 

  2. Dralle D, Müller H, Zierski J, Klug N (1985) Intrathecal baclofen for spasticity. Lancet 2: 1003

    Google Scholar 

  3. Erickson DL, Lo J, Michaelson M (1989) Control of intractable spasticity with intrathecal morphine sulfate. Neurosurgery 24: 236–238

    PubMed  Google Scholar 

  4. Frankel HL, Hancock DO, Hyslop G, Melzak J, Michaelis LS, Ungar GH, Vernon JOS, Walsh JJ (1969) The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia. I. Paraplegia 5: 93–95

    Google Scholar 

  5. Gros C (1979) Spasticity — clinical classification and surgical treatment. In: Krayenbühl Het al (eds) Advances and technical standards in neurosurgery, vol 6. Springer, Wien New York, pp 55–97

    Google Scholar 

  6. Kerr DIB, Ong J, Prager RH (1987) Phaclofen: a peripheral and central baclofen antagonist. Brain Res 405: 150–154

    PubMed  Google Scholar 

  7. Kroin JS, Penn RD, Bessinger RL, Arzbaecher RC (1984) Reduced spinal reflexes following intrathecal baclofen in the rabbit. Exp Brain Res 540: 191–194

    Google Scholar 

  8. Latash ML, Penn RD, Corcos DM, Gottlieb GL (1990) Effects of intrathecal baclofen on voluntary motor control in spastic paresis. J Neurosurg 72: 388–392

    PubMed  Google Scholar 

  9. Lazorthes Y (1988) Chronic intrathecal administration of baclofen in treatment of severe spasticity. In: Müller Het al (eds) Local-spinal therapy of spasticity. Springer, Berlin Heidelberg New York Tokyo, pp 215–222

    Google Scholar 

  10. Lazorthes Y, Sallerin-Caute B, Verdie JC, Bastide R, Carillo JP (1990) Chronic intrathecal baclofen administration for control of severe spasticity. J Neurosurg 72: 393–402

    PubMed  Google Scholar 

  11. Müller H, Zierski J (1988) Pumps in pharmacotherapy. In: Müller Het al (eds) Local-spinal therapy of spasticity. Springer, Berlin Heidelberg New York Tokyo, pp 97–123

    Google Scholar 

  12. Müller H, Zierski J, Dralle D, Borner U, Hoffmann O (1987) The effect of intrathecal baclofen on electrical muscle activity in spasticity. J Neurol 234: 348–352

    PubMed  Google Scholar 

  13. Müller H, Zierski J, Dralle D, Hoffmann O, Michaelis G (1988) Intrathecal baclofen in spasticity. In: Müller Het al (eds) Local-spinal therapy of spasticity. Springer, Berlin Heidelberg New York Tokyo, pp 155–214

    Google Scholar 

  14. Müller H, Zierski J, Dralle D, Kaub D, Mutschier E (1988) Pharmacokinetics of intrathecal baclofen. In: Müller Het al (eds) Local-spinal therapy of spasticity. Springer, Berlin Heidelberg New York Tokyo, pp 223–226

    Google Scholar 

  15. Müller-Schwefe G (1988) Physostigmine reversal of baclofen-induced sedation. In: Müller Het al (eds) Local-spinal therapy of spasticity. Springer, Berlin Heidelberg New York Tokyo, pp 253

    Google Scholar 

  16. Müller-Schwefe G, Penn RD (1989) Physostigmine in the treatment of intrathecal baclofen overdose. J Neurosurg 71: 273–275

    PubMed  Google Scholar 

  17. Ochs G, Struppler A, Meyerson BA, Linderoth B, Gybels J, Gardner BP, Teddy P, Jamous A, Weinmann P (1989) Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study. J Neurol Neurosurg Psychiatry 52: 933–939

    PubMed  Google Scholar 

  18. Penn RD (1988) Chronic intrathecal baclofen for severe rigidity and spasms. In: Müller Het al (eds) Local-spinal therapy of spasticity. Springer, Berlin New York Tokyo, pp 151–153

    Google Scholar 

  19. Penn RD (1988) Intrathecal baclofen for severe spasticity. Ann NY Acad Sci 531: 157–166

    PubMed  Google Scholar 

  20. Penn RD, Kroin JS (1984) Intrathecal baclofen alleviates spinal cord spasticity. Lancet 1: 1078

    PubMed  Google Scholar 

  21. Penn RD, Kroin JS (1985) Continuous intrathecal baclofen for severe spasticity. Lancet 2: 125–127

    PubMed  Google Scholar 

  22. Penn RD, Kroin JS (1987) Long-term intrathecal baclofen infusion for treatment of spasticity. J Neurosurg 66: 181–185

    PubMed  Google Scholar 

  23. Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, Kroin JS (1989) Intrathecal baclofen for severe spinal spasticity. New Engl J Med 320: 1517–1521

    PubMed  Google Scholar 

  24. Price GW, Wilkin GP, Turnbull MJ, Bowery NG (1984) Are baclofen-sensitive GABA-B receptors present on primary afferent terminals of the spinal cord? Nature 307: 71–74

    PubMed  Google Scholar 

  25. Scott BA, Pulliam MW (1987) Management of spasticity and painful spasms in paraplegia. In: Tindall GT (ed) Contemporary Neurosurgery, vol 9, no 11. Williams and Wilkins, Baltimore

    Google Scholar 

  26. Zieglgänsberger W (1987) Dorsal horn neuropharmacology: Baclofen and morphine. Ann NY Acad Sci 531: 150–156

    Google Scholar 

  27. Zierski J, Müller H (1988) Implantation of ports and pumps. Technique for intrathecal administration of drugs. In: Müller Het al (eds) Local-spinal therapy of spasticity. Springer, Berlin Heidelberg New York Tokyo, pp 125–136

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sahuquillo, J., Muxi, T., Noguer, M. et al. Intraspinal baclofen in the treatment of severe spasticity and spasms. Acta neurochir 110, 166–173 (1991). https://doi.org/10.1007/BF01400686

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01400686

Keywords

Navigation